U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155694) titled 'Role of Finerenone in African American Veterans With Diabetic Kidney Disease' on Aug. 13.
Brief Summary: Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone or combination therapy.
Secondary Objectives: (1). Correlate changes in exosome-based PSP with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. (2) with systemic inflammatory ...